I Couldn’t See Well. Part 2

Treatment
Macular degeneration is still a poorly understood condition. Her local doctor could not treat her, so he referred Mrs. Cox to a specialist in the nearest big city, about 100 miles away. She went with hopes of a cure. But she learned that any improvement would be limited. “Once I went to see this new doctor, I thought that I’d be able to see again. But he said that my eyesight would never be the same.” Read the rest of this entry »

Introduction. Part 2

Until recently, the treatment standard for chronic hepatitis C infection has been alpha intereron monotherapy. Approximately 40% of interferon-treated patients show biochemical and virological response at the end of therapy; however, more than one-half of these responders relapse after treatment cessation. Read the rest of this entry »

Introduction. Part 1

Donald M. Jensen, MD, Chair and Program CME Advisor

It is estimated that about 4 million Americans or about 2% of the population are infected with the hepatitis C virus. Following acute infection, up to 75 to 85% of patients develop chronic hepatitis C, predisposing them to chronic complicated liver disease and, in some instances, premature death due to cirrhosis and hepatocellular cancer. Read the rest of this entry »

Cancer, Genes or Environment?

In the current trend toward explaining diseases genetically with high enthusiasm for the Human Genome Project, the question arises; what is the role of heredity in human disease, in contradistinction to the role of environment?

Read the rest of this entry »